 "Glenmark Pharma gets USFDA approval for nervous system stimulant drug")
Drug major Glenmark Pharma on Thursday said it has received final approval from the US health regulator for central nervous system stimulant drug Amphetamine Sulfate tablets.
The approved product is a generic version of Evekeo tablets of Arbor Pharmaceuticals LLC.
Glenmark Pharmaceuticals Ltd has been granted final approval by the United States Food and Drug Administration (USFDA) for Amphetamine Sulfate tablets USP in the strengths of 5 mg and 10 mg, it said in a regulatory filing.
Quoting IQVIA sales data for the 12 month period ending November 2020, Glenmark said Evekeo Tablets, 5 mg and 10 mg market achieved annual sales of approximately USD 21.5 million.
Glenmark's current portfolio consists of 168 products authorised for distribution in the US marketplace and 43 ANDA's pending approval with the USFDA.
Shares of Glenmark Pharma were trading 1.44 per cent lower at Rs 478.50 apiece on BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app